Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by RealPharma. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by RealPharma or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Inside the CMC Black Box: A Deep Dive with Reza Oliyai

47:23
 
Share
 

Manage episode 505151268 series 3535889
Content provided by RealPharma. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by RealPharma or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

🎙️ Episode Title:

Inside the CMC Black Box: A Deep Dive with Reza Oliyai

🧾 Show Notes:

What exactly is CMC — and why is it behind more FDA rejections than any other category?

In this episode of RealPharma, hosts Na-Ri Oh and Ian Wendt sit down with Dr. Reza Oliyai, former SVP of Pharmaceutical & Biologics Operations at Gilead Sciences, and now Founder & CEO of Oliyai Consulting, to demystify the world of Chemistry, Manufacturing, and Controls (CMC).

With over three decades of experience and a role in advancing 200+ drug candidates and 27 product launches, Reza offers a front-row seat to what goes wrong — and right — in the drug development journey.

🔍 In this episode, we explore:
  • What CMC really means — and why the "controls" part is most overlooked

  • Why 74% of FDA complete response letters involve CMC issues

  • The pitfalls of the “Phase 1 mentality” in late-stage development

  • AI in CMC: helpful tool or overhyped distraction?

  • How to evaluate CDMO partners (and why big pharma’s pick might be your wrong fit)

  • The evolving geopolitical landscape and its impact on global manufacturing

  • What startups, investors, and boards need to understand about CMC before it’s too late

  • Career advice: what it takes to lead in this increasingly complex field

🧠 Key Quote:

“CMC is a black box to most executives. That’s a problem. Because it’s also the number one reason drugs get delayed.” — Dr. Reza Oliyai

Whether you're in manufacturing, regulatory, executive leadership, or just trying to understand what actually gets a drug to market — this episode is a must-listen.

🔗 Resources & Mentions: 👤 About Our Guest:

Dr. Reza Oliyai is a globally recognized leader in pharmaceutical operations, with deep expertise across small molecules, biologics, ADCs, peptides, siRNA, and more. After 28 years at Gilead Sciences, he now advises over 100 organizations worldwide through his firm, Oliyai Consulting.

  continue reading

49 episodes

Artwork
iconShare
 
Manage episode 505151268 series 3535889
Content provided by RealPharma. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by RealPharma or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

🎙️ Episode Title:

Inside the CMC Black Box: A Deep Dive with Reza Oliyai

🧾 Show Notes:

What exactly is CMC — and why is it behind more FDA rejections than any other category?

In this episode of RealPharma, hosts Na-Ri Oh and Ian Wendt sit down with Dr. Reza Oliyai, former SVP of Pharmaceutical & Biologics Operations at Gilead Sciences, and now Founder & CEO of Oliyai Consulting, to demystify the world of Chemistry, Manufacturing, and Controls (CMC).

With over three decades of experience and a role in advancing 200+ drug candidates and 27 product launches, Reza offers a front-row seat to what goes wrong — and right — in the drug development journey.

🔍 In this episode, we explore:
  • What CMC really means — and why the "controls" part is most overlooked

  • Why 74% of FDA complete response letters involve CMC issues

  • The pitfalls of the “Phase 1 mentality” in late-stage development

  • AI in CMC: helpful tool or overhyped distraction?

  • How to evaluate CDMO partners (and why big pharma’s pick might be your wrong fit)

  • The evolving geopolitical landscape and its impact on global manufacturing

  • What startups, investors, and boards need to understand about CMC before it’s too late

  • Career advice: what it takes to lead in this increasingly complex field

🧠 Key Quote:

“CMC is a black box to most executives. That’s a problem. Because it’s also the number one reason drugs get delayed.” — Dr. Reza Oliyai

Whether you're in manufacturing, regulatory, executive leadership, or just trying to understand what actually gets a drug to market — this episode is a must-listen.

🔗 Resources & Mentions: 👤 About Our Guest:

Dr. Reza Oliyai is a globally recognized leader in pharmaceutical operations, with deep expertise across small molecules, biologics, ADCs, peptides, siRNA, and more. After 28 years at Gilead Sciences, he now advises over 100 organizations worldwide through his firm, Oliyai Consulting.

  continue reading

49 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play